|02/20/18||IRIDEX to Report Fourth Quarter and 2017 Financial Results on March 8, 2018|
|MOUNTAIN VIEW, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8, 2018. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 fo... |
|01/09/18||IRIDEX Announces Infringement Lawsuit Against Quantel|
|MOUNTAIN VIEW, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) announced today that it has filed a lawsuit against Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. in the U.S. District Court for the Northern District of California. The lawsuit alleges that Quantel products infringe U.S. Patent No. 7,771,417, that Quantel breached an earlier agreement between the parties, and that Quantel has infringed Iridex's MicroPulse® trademark, Registration No. 45501... |
|01/08/18||IRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year|
|MOUNTAIN VIEW, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 30, 2017.
Total revenue for the fourth quarter of 2017 expected to be $11.0 to $11.1 million
Total revenue for 2017 expected to be $42.3 to $42.4 million
Approximately 133 Cyclo G6 glaucoma laser systems and 10,600 G6 probes were shipped in the fourth quarter of 2017